Few would place Recursion Pharmaceuticals ( RXRX +8.44%), a little-known biotech company, in the same league as these tech ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

We recently published 10 Big Names Crushing the Market. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the ...

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

The investing party is the Wall Street darling chipmaker of the moment, Nvidia (NASDAQ: NVDA). It disclosed that as of Dec. 31, it held investments in three companies developing artificial ...